TLDR BerEP4 and CD34 staining can help tell apart tricholemmoma from basal cell carcinoma.
The study investigated the use of immunohistochemical markers CD34 and BerEP4 to differentiate between basaloid tricholemmoma and basal cell carcinoma (BCC). It included 55 tricholemmomas (15 basaloid) and compared their profiles with nodular BCCs. BerEP4 was focally positive in only 7.7% of tricholemmomas but widespread in 90.8% of BCCs. CD34 was expressed in 98.1% of tricholemmomas and negative in all BCCs. EMA staining was not effective for differentiation. The presence of 5 or more Merkel cells was more common in tricholemmomas (40.1%) than in BCCs (4.3%). The study concluded that CD34 and BerEP4 are useful markers for distinguishing between these two conditions.
5 citations,
May 2013 in “The American Journal of Dermatopathology” The author now believes tricholemmal carcinoma is a rare type of infundibular squamous cell carcinoma and more research is needed on these tumors.
7 citations,
March 2017 in “Journal of dermatology” The conclusion is that accurately identifying folliculosebaceous tumors requires understanding their clinical signs and microscopic features.
4 citations,
January 2019 in “Annals of Dermatology” Higher levels of MiR-92a-1-5p and miR-328-3p found in female hair loss patients.
4 citations,
August 2017 in “Journal of cutaneous pathology” An 8-year-old girl had a rare, benign skin tumor on her forehead.
2 citations,
June 2022 in “Life” A 14-year-old boy is the youngest person reported with a rare, benign tumor related to hair follicles, usually found in older people.
July 2016 in “American Journal of Dermatopathology” The meeting showcased rare skin disease cases, highlighting the need for accurate diagnosis and treatment.
